Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens
| Autor: | Roos S. G. Sablerolles, Abraham Goorhuis, Corine H. GeurtsvanKessel, Rory D. de Vries, Anke L. W. Huckriede, Marion P. G. Koopmans, Melvin Lafeber, Douwe F. Postma, Debbie van Baarle, Leo G. Visser, Virgil A. S. H. Dalm, Neeltje A. Kootstra, Wim J. R. Rietdijk, P. Hugo M. van der Kuy |
|---|---|
| Přispěvatelé: | Translational Immunology Groningen (TRIGR), Microbes in Health and Disease (MHD), Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, APH - Global Health, Experimental Immunology, Pharmacy, Internal Medicine, Virology |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Immunology Trial protocol Immunization Secondary REACTOGENICITY Heterologous Prime (order theory) law.invention Study Protocol Ad26.Cov2.S Randomized controlled trial SDG 3 - Good Health and Well-being law Internal medicine Homologous vaccination regimen Humans Immunology and Allergy Medicine Heterologous vaccine regimen BNT162 Vaccine mRNA1273 & nbsp Reactogenicity Ad26COVS1 business.industry SARS-CoV-2 Immunogenicity COVID-19 RC581-607 mRNA1273 randomized clinical trial Vaccination Immunologic diseases. Allergy business BNT162.b2 2019-nCoV Vaccine mRNA-1273 |
| Zdroj: | Frontiers in Immunology, 12:753319. Frontiers Media SA Frontiers in immunology, 12:753319. Frontiers Media S.A. Frontiers in Immunology, Vol 12 (2021) Frontiers in Immunology Frontiers in Immunology, 12:753319. Frontiers Media S.A. Frontiers in Immunology, 12. FRONTIERS MEDIA SA |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2021.753319 |
| Popis: | The present protocol study was used to summarize the findings of other major COVID-19 vaccination trials and provide an outline of our multicenter, single-blind, randomized controlled trial: the SWITCH trial. In the SWITCH, we compare the immunogenicity and reactogenicity of heterologous versus homologous vaccination strategies of COVID-19 vaccines. We recruit Health Care Workers (HCWs) who received ad.26.Cov2.S as their prime (first vaccination). We randomize HCWs in four groups: no boost (second vaccination), ad.26.Cov2.S, mRNA1273, and BNT162b2). The full protocol of the SWITCH trial can be found in the supplementary material. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|